Natera Stock
Natera, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Steven Leonard Chapman
- Employees
- 6,138
- Market cap
- $56.7 B
- IPO
- 01/07/2015
Natera, Inc. is a company operating in the U.S. healthcare/medical diagnostics and research sector, headquartered in Austin, Texas. Its portfolio includes molecular testing services such as the Panorama test for prenatal diagnostics and Signatera technology for analyzing circulating tumor DNA (ctDNA). Additional…
AI-generated company profile based on the figures on this page, last updated on 07/08/2026. Not investment advice.
Natera stock: price history
1D
-2.8%
1W
-1.8%
1M
+13.9%
6M
+88.8%
YTD
+71.7%
1Y
+117.9%
2Y
+210.4%
5Y
+255.2%
10Y
+3,744.1%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~28% stronger price swings than usual
Natera stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
1 more assignment (Enabler/Second row) Pro-only.
Natera, Inc. offers specialized molecular diagnostic services based on cutting-edge technology platforms. Its portfolio includes prenatal testing such as the Panorama test, as well as specialized procedures for cancer early detection using circulating tumor DNA (Signatera) and for monitoring organ rejection (Prospera). In addition to selling individual diagnostic units, the company provides Constellation, a cloud-based software platform that enables partners to access proprietary algorithms. The business model is primarily supported by transactional revenues from diagnostic tests, with specialized technologies and bioinformatics expertise creating a significant competitive advantage through intellectual property.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- Low
- Customer concentration
- Unknown
Ask the agents about Natera
Analyst assessment of Natera
PRICE TARGET LOW
US$245.00
CONSENSUS
US$364.40
MEDIAN
US$350.00
PRICE TARGET HIGH
US$475.00
0
STRONG BUY
25
BUY
3
HOLD
0
SELL
0
STRONG SELL
28
TOTAL · Buy
As of: 14/10/2026
Natera stock metrics
P/E
-289.29
P/B
30.95
EV/EBITDA
-312.57
RETURN ON EQUITY
-3.7%
NET MARGIN
-8.9%
DEBT/EQUITY
0.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.6%
FLOAT SHARES
134,879,433
AVG. DAILY VOLUME (30D)
1,672,803
Insider transactions (SEC)
Rabinowitz Matthew
Rabinowitz Matthew
Rabinowitz Matthew
Rabinowitz Matthew
Rabinowitz Matthew
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.8%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Natera stock
What does Natera do?
Natera, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Steven Leonard Chapman, the company employs around 6,138 people.
The IPO was on 01/07/2015; the stock trades on NASDAQ under the ticker NTRA.
What do analysts say about Natera stock?
28 analysts rate the stock, the consensus is Buy (as of 14/10/2026).
The average price target is US$364.40, ranging from US$245.00 to US$475.00, with a median of US$350.00.
This is an external assessment, not a statement by Market Jury.
When does Natera report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 28% stronger than usual.
Does Natera pay a dividend?
No, Natera currently does not pay a dividend.
Which stocks are comparable to Natera?
Comparable stocks include Thermo Fisher Scientific, Danaher, Agilent Technologies, IQVIA Holdings, Waters, Illumina, IDEXX Laboratories and Mettler-Toledo International.
How can I get Natera stock analyzed?
Clicking "Analyze stock" lets five strategies assess Natera against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.